EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study

Timothy S Bailey iD, David R Liljenquist, Douglas S Denham, Ronald L Brazg, Sorin Ioacara, James Masciotti, Samanwoy Ghosh-Dastidar, Katherine S Tweden iD, Francine R Kaufman

Diabetes Technology & Therapeutics · 2025-05 · 27 (5) · 407-411

DOI: 10.1089/dia.2024.0592 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 01.05.2025. Verfasst von Timothy S Bailey und 8 weiteren Autor:innen. Beteiligte Einrichtung: Headlands Research California-AMCR Institute, Escondido, California, USA. Hauptthemen laut MEDLINE: Blood Glucose Self-Monitoring, Blood Glucose, Diabetes Mellitus, Type 1, Insulin Infusion Systems. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes. Accuracy and adverse events (AEs) were assessed during 14 in-clinic visits comparing CGM and Yellow Springs Instrument reference glucose measurements, including during hyperglycemia and hypoglycemia challenges. In total, 110 participants were implanted with the Eversense 365 CGM System. The overall mean absolute relative difference was 8.8% with primarily one calibration per week. The confirmed alert detection rate at 70 mg/dL was 96.6%, and at 180 mg/dL, it was 97.9%. Ninety percent of the sensors survived 365 days. Interoperable CGM special controls were met. No related serious AEs were reported. The Eversense 365 CGM was shown to be safe and accurate through 1 year with primarily one calibration per week.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Glucose Self-MonitoringBlood GlucoseDiabetes Mellitus, Type 1Insulin Infusion SystemsInsulinHumansMaleMiddle AgedFemaleProspective StudiesAdultAgedHypoglycemiaReproducibility of ResultsHypoglycemic AgentsContinuous Glucose Monitoring

Stichwörter der Autor:innen

CGMeversenseiCGMimplantable sensor

Substanzen

Blood GlucoseHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Headlands Research California-AMCR Institute, Escondido, California, USA.
  • Rocky Mountain Research Center, Idaho Falls, Idaho, USA.
  • Flourish Inc, San Antonio, Texas, USA.
  • Rainer Clinical Research Center, Renton, Washington, USA.
  • Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Elias Emergency University Hospital, Bucharest, Romania.

ORCID-Profile: Timothy S Bailey, Katherine S Tweden

Zitieren

APA

Bailey, T. S., Liljenquist, D. R., Denham, D. S., Brazg, R. L., Ioacara, S., Masciotti, J., Ghosh-Dastidar, S., Tweden, K. S., & Kaufman, F. R. (2025). Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics, 27(5), 407-411. https://doi.org/10.1089/dia.2024.0592

Vancouver

Bailey TS, Liljenquist DR, Denham DS, Brazg RL, Ioacara S, Masciotti J, et al. Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics. 2025;27(5):407-411. doi:10.1089/dia.2024.0592

BibTeX
@article{Bailey2025,
  author = {Bailey, Timothy S and Liljenquist, David R and Denham, Douglas S and Brazg, Ronald L and Ioacara, Sorin and Masciotti, James and Ghosh-Dastidar, Samanwoy and Tweden, Katherine S and Kaufman, Francine R},
  title = {Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study},
  journal = {Diabetes Technology & Therapeutics},
  year = {2025},
  volume = {27},
  number = {5},
  pages = {407--411},
  doi = {10.1089/dia.2024.0592}
}
Kostenlos starten →